A dire shortage of more than 12 different HRT medications has prompted the Therapeutic Goods Administration to advise doctors to limit prescribing the medications for new patients.
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.